JMP Securities analyst Reni Benjamin initiated coverage of Inhibrx with a Market Perform rating without a price target following Sanofi’s acquisition of INBRX-101 and subsequent spinout of the remaining assets. The analyst believes the company is well capitalized to develop its hexavalent OR40 agonist and DR5 agonist but sees the shares as fairly valued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBX: